Who
Patrick J. Crutcher
Director
Company insider
Files Form 4 as: Director, Jasper Therapeutics; VP, Business Development, Avalo Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 25 Sep 2018
- Last trade
- 31 Jul 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 4 Aug 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 31 Jul 2026filed 4 Aug 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 20 Jul 2026filed 20 Jul 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —888 | filing |
| 20 Jul 2026filed 20 Jul 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —888 | filing |
| 16 Jul 2026filed 20 Jul 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Jul 2026filed 20 Jul 2026 | JSPR Jasper Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Apr 2019filed 2 Apr 2019 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —145,000 at $0.00 | filing |
| 20 Dec 2018filed 2 Apr 2019 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code D | —6,871 | filing |
| 25 Sep 2018filed 4 Oct 2018 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,641,642 | filing |
| 25 Sep 2018filed 27 Sep 2018 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,645,286 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.